Expand KYTX Menu
KYTX MENU

KYTX Latest Press Releases

-- December 15, 2024 --

KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Business Wire 4:00 PM
KYTX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Globe Newswire 10:55 AM

-- December 14, 2024 --

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action KYTX Globe Newswire 12:06 PM

-- December 13, 2024 --

KYVERNA THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX PRNewswire 10:50 PM
KYTX INVESTOR ALERT: Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PRNewswire 10:15 PM
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors Business Wire 8:14 PM
Kyverna Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the KYTX Class Action Lawsuit Globe Newswire 4:18 PM
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth PRNewswire 4:05 PM
KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PRNewswire 4:00 PM
DEADLINE ALERT for BOOM, KYTX, and MQ: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders Globe Newswire 12:18 PM
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX PRNewswire 5:45 AM

-- December 12, 2024 --

INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel Globe Newswire 6:34 PM
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Securities Fraud Lawsuit PRNewswire 5:57 PM
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors Business Wire 3:00 PM
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors Business Wire 2:03 PM
Faruqi & Faruqi Reminds Kyverna Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX PRNewswire 11:56 AM
KYTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Business Wire 5:50 AM

-- December 11, 2024 --

KYVERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. and Encourages Investors to Contact the Firm Globe Newswire 9:00 PM
The Law Offices of Frank R. Cruz Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors Business Wire 7:04 PM
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX Globe Newswire 5:59 PM
KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Globe Newswire 4:00 PM
KYTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Kyverna Class Action Lawsuit Globe Newswire 2:44 PM
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PRNewswire 10:12 AM

-- December 10, 2024 --

KYVERNA THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX Business Wire 8:32 PM
Kyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. February 7, 2025 Deadline to file Lead Plaintiff Motion. Globe Newswire 6:12 PM
Rosen Law Firm Urges Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights Business Wire 4:19 PM
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. PRNewswire 3:23 PM
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) INVESTOR ALERT: Investors With Large Losses in Kyverna Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights Globe Newswire 3:05 PM
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. (KYTX) Globe Newswire 2:27 PM
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm Business Wire 1:37 PM
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics Business Wire 1:33 PM
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm Globe Newswire 11:35 AM

-- December 9, 2024 --

Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit Globe Newswire 6:38 PM
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Business Wire 6:35 PM

-- November 14, 2024 --

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 PRNewswire 10:01 AM

-- November 13, 2024 --

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results PRNewswire 4:14 PM

-- October 21, 2024 --

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors PRNewswire 8:00 AM

-- September 18, 2024 --

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 PRNewswire 8:00 AM

-- August 21, 2024 --

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences PRNewswire 4:05 PM

-- August 12, 2024 --

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results PRNewswire 4:08 PM
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis PRNewswire 4:05 PM

-- July 15, 2024 --

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome PRNewswire 4:05 PM